Equillium logo
Equillium EQ
$ 1.16 1.75%

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Equillium Financial Ratios 2011-2026 | EQ

Annual Financial Ratios Equillium

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-6.4 -0.3 -2.8 -4.8 -3.2 -7.6 -4.4 - - - - - -

P/S

2.3 1.3 - - - - - - - - - - -

EPS

-0.4 -1.9 -1.4 -1.5 -1.5 -1.1 - - - - - - -

EV (Enterprise Value)

89.5 M 8.28 M 77.1 M 133 M 83.4 M 74.3 M 9.4 M - - - - - -

EBITDA per Share

-0.41 -1.84 -1.31 -1.16 -1.54 -0.706 - - - - - - -

EV/EBITDA

-1.5 -4.5 -3.0 -8.4 -3.9 - - - - - -

PEG

- -6.99 0.09 3.61 5.62 - - - - - -

P/B

3.8 0.7 1.6 2.0 2.0 1.5 -4.5 - - - - - -

P/CF

-3.9 -2.4 -3.4 -5.7 -3.6 -13.3 -15.1 - - - - - -

ROE %

-59.08 -195.44 -58.72 -42.68 -61.17 -20.41 100.43 - - - - - -

ROA %

-26.39 -79.61 -45.73 -34.90 -46.09 -19.73 -31.63 - - - - - -

ROCE %

-64.33 -194.34 -56.82 -37.79 -51.74 -13.23 -34.36 - - - - - -

Current Ratio

1.8 1.7 4.5 11.8 14.3 33.1 12.6 - - - - - -

DSO

33.2 32.9 - - - - - - - - - - -

Operating Cycle

33.2 32.9 - - - - - - - - - - -

Cash Conversion Cycle

33.2 32.9 - - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Equillium

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.06 -0.16 -0.24 - - 0.01 -0.08 - -0.11 -0.1 -0.11 - -0.4 -0.41 -1.17 - -0.35 -0.31 -0.33 -0.36 -0.31 -0.37 -0.45 -0.44 -0.35 -0.35 -0.34 -0.31 -0.44 -0.16 -0.15 -0.1 -0.01 -0.1 - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - -0.25 - - - -0.08 - - - -0.12 - -0.38 -0.39 -1.17 - -0.33 -0.3 -0.32 - -0.3 -0.37 -0.42 - -0.36 -0.37 -0.37 - -0.2 -0.1 -0.1 - -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-209.02 -195.38 -79.79 -10.91 -26.29 -41.65 -56.13 -41.24 -89.73 -122.83 -145.53 -154.67 -168.24 -133.31 -109.03 -34.15 -46.92 -42.80 -41.25 -42.68 -47.99 -52.92 -58.17 -61.17 -50.78 -43.98 -32.20 -20.41 36.41 50.24 52.96 55.39 6.26 - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-110.30 -98.06 -50.68 -5.20 -11.92 -18.62 -25.40 -17.90 -45.97 -67.33 -84.26 -101.10 -112.22 -95.26 -81.81 -28.71 -39.15 -35.75 -34.14 -34.90 -38.08 -41.19 -44.55 -46.09 -39.90 -36.39 -28.09 -19.73 -27.77 -22.42 -19.79 -17.44 -1.97 - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - - - - - - - -47.01 -94.01 -127.67 -151.59 -164.60 -130.60 -107.38 -32.90 -42.23 -38.55 -37.58 -29.46 -44.57 -50.35 -56.22 -45.54 -48.97 -37.29 -23.69 -6.75 -3.04 4.11 5.84 3.72 3.72 - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

9.7 1.7 2.7 3.9 3.0 2.1 1.9 1.8 1.8 1.9 1.7 1.7 2.4 2.8 3.4 4.5 5.5 6.6 7.1 5.5 5.5 5.5 5.5 4.1 4.1 4.1 4.1 30.1 30.1 30.1 30.1 0.8 0.8 - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - 40.9 36.0 37.5 - 38.6 35.8 32.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - 40.9 36.0 37.5 - 38.6 35.8 32.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - 40.9 36.0 37.5 - 38.6 35.8 32.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Equillium, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 1.65 7.91 % $ 92.9 M chinaChina
AstraZeneca PLC AstraZeneca PLC
AZN
$ 93.52 -1.2 % $ 96.9 B britainBritain
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.52 -16.3 % $ 388 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.59 1.99 % $ 8.64 B australiaAustralia
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Biogen Biogen
BIIB
$ 184.48 -1.67 % $ 26.9 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 102.17 2.32 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.25 1.67 % $ 9.25 B israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 207.49 2.22 % $ 5 B danmarkDanmark
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.84 0.46 % $ 714 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 37.35 -0.4 % $ 3.86 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.59 -6.54 % $ 1.65 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.22 -4.2 % $ 116 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.43 6.09 % $ 1.43 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.66 2.28 % $ 1.53 B britainBritain
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 66.05 2.3 % $ 8.83 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 55.11 3.49 % $ 4.45 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.14 -1.06 % $ 110 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.17 2.47 % $ 4.65 B schweizSchweiz
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 632.29 0.09 % $ 47.9 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 0.81 1.96 % $ 10.7 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.7 2.27 % $ 17 M usaUSA